MSC MBA - Mirum Pharmaceuticals Chief Officer
| MIRM Stock | USD 46.22 0.43 0.92% |
Insider
MSC MBA is Chief Officer of Mirum Pharmaceuticals
| Age | 54 |
| Address | 950 Tower Lane, Foster City, CA, United States, 94404 |
| Phone | 650 667 4085 |
| Web | https://www.mirumpharma.com |
Mirum Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.091) % which means that it has lost $0.091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3984) %, meaning that it created substantial loss on money invested by shareholders. Mirum Pharmaceuticals' management efficiency ratios could be used to measure how well Mirum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.2. At this time, Mirum Pharmaceuticals' Fixed Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Keith MD | X4 Pharmaceuticals | 53 | |
| Annelise Vuidepot | Immunocore Holdings | N/A | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Eric McIntyre | Arcutis Biotherapeutics | N/A | |
| Bhaskar Chaudhuri | Arcutis Biotherapeutics | 69 | |
| Oliver Daltrop | MoonLake Immunotherapeutics | N/A | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| David Osborne | Arcutis Biotherapeutics | 63 | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
| Debra Nielsen | Immunocore Holdings | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Jorge Silva | MoonLake Immunotherapeutics | 46 | |
| Francis Conway | Larimar Therapeutics | N/A | |
| John McKune | Kalvista Pharmaceuticals | 48 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.091 |
Mirum Pharmaceuticals Leadership Team
Elected by the shareholders, the Mirum Pharmaceuticals' board of directors comprises two types of representatives: Mirum Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mirum. The board's role is to monitor Mirum Pharmaceuticals' management team and ensure that shareholders' interests are well served. Mirum Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mirum Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter MBA, Chief Officer | ||
| Eric MBA, Chief Officer | ||
| Ian Clements, Chief Officer | ||
| Paul Ross, Chief Officer | ||
| Joanne MD, Chief Officer | ||
| MSC MBA, Chief Officer | ||
| Christopher Peetz, CEO Director | ||
| Pamela Vig, Chief Research | ||
| Erin Campany, Senior Resources | ||
| Vinita Kumar, Senior Quality | ||
| Andrew McKibben, Vice Finance | ||
| JeanLuc Girardet, Senior Operations |
Mirum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mirum Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.091 | ||||
| Profit Margin | (0.33) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 2.27 B | ||||
| Shares Outstanding | 48 M | ||||
| Shares Owned By Insiders | 2.24 % | ||||
| Shares Owned By Institutions | 97.76 % | ||||
| Number Of Shares Shorted | 6.97 M | ||||
| Price To Earning | (5.20) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.